Amphastar Pharmaceuticals, Inc.
Every calculator, already run for AMPH
Open the full toolkit →You have the numbers on AMPH. Get the argument.
A written report on which of these readings actually decide the outcome for Amphastar Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
7 analysts covering AMPHAnalyst Price Target Disagreement for Amphastar Pharmaceuticals, Inc.
Wall Street's bull case implies +27% from the current price; the bear case implies -15%. A 42% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for AMPH
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for…
AMPH — frequently asked
Is AMPH a buy right now?
Wall Street's consensus rating on Amphastar Pharmaceuticals, Inc. is none across 7 analysts, with a mean price target of $22.50 (-5% vs. the current $23.62). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is AMPH overvalued?
AMPH trades at 14.0x trailing earnings, against a DCF fair value of $167 per share. The current price implies -10% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is AMPH's next earnings date?
Amphastar Pharmaceuticals, Inc. is next scheduled to report earnings around Nov 5, 2026. A full AMPH research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Amphastar Pharmaceuticals, Inc.?
Analysts covering Amphastar Pharmaceuticals, Inc. (AMPH) range from a bear-case target of $20.00 to a bull-case high of $30.00, with a mean consensus target of $22.50 across 6 analysts. The spread of $10.00 (42% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Amphastar Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Amphastar Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full AMPH research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Amphastar Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.